December 14, 2017 — iCAD Inc. recently announced that customer adoption of its PowerLook Tomo Detection is gaining momentum. Driven by its ability to leverage artificial intelligence (AI), the solution optimizes digital breast tomosynthesis (DBT) reading efficiency and improves confidence of radiologists. This efficiency enables users to streamline workflow and supports faster, more confident detection of breast cancer. PowerLook Tomo Detection is the first and only U.S. Food and Drug Administration (FDA)-approved concurrent-read cancer detection solution for DBT, according to the company. During the 2017 Radiological Society of North America (RSNA) Annual Meeting, Nov. 26-Dec. 1 in Chicago, Senthil Periaswamy, Ph.D, vice president of research at iCAD, presented on AI with breast tomosynthesis in the meeting’s Machine Learning Theater. The company also showcased the complete PowerLook Breast Health Solutions suite in its booth.
iCAD CEO Ken Ferry said the mammography AI solution is clinically proven to optimize radiologists’ image reading and interpretation by reducing DBT read-time by an average of 29.2 percent. He added that since its FDA approval in March, PowerLook Tomo Detection has been implemented by a number of leading breast health provider organizations throughout the United States.
“PowerLook Tomo Detection is an important addition. When you’re confronted with a lot of breast tomosynthesis exams to read daily, you can get fatigued. Now, depending on the size of the breast, I am able to cut down my reading time anywhere from 25-50 percent,” said Katherine Hall, M.D., diagnostic radiologist and co-director of mammography, East Division, at Southwest Diagnostic Imaging Center.
Recently named 2017 Product of the Year by the New Hampshire High Technology Council, PowerLook Tomo Detection utilizes a trained algorithm developed through deep learning that automatically analyzes each tomosynthesis plane. Suspicious areas identified are then blended into a 2-D synthetic image to provide radiologists with a single, highly sensitive, enhanced image that is used to easily navigate the tomosynthesis datasets. While PowerLook Tomo Detection is currently only available for GE Healthcare’s DBT platforms, iCAD is developing a multi-vendor solution that is expected to be available in 2018.
In addition to PowerLook Tomo Detection, iCAD’s suite of PowerLook Breast Health Solutions includes PowerLook Mammo Detection, which supports rapid and accurate cancer detection with 2-D full-field digital mammography; and PowerLook Density Assessment, which provides a standardized assessment of breast tissue to assist radiologists in determining the patient’s appropriate breast density category. The solution suite provides clinicians with a wide range of tools for cancer detection and analysis that enhances workflow and improves overall reading productivity.
For more information: www.icadmed.com
April 15, 2026 
